Pro members get same-minute coverage on the stocks they track. Free plans update twice a day.
Get ProCounts of positive, neutral, and negative news items. Not a price chart.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
Showing 2 stories from the week of 8 Jun
Show allThe items moving the net sentiment the most, by direction and influence.
CMS Proposes Extending Medicare Drug Price Negotiations to 2029, Pressuring Big Pharma Revenue
Drug pricing / FDA / IRA · High influence · Long term
US Court Upholds Drug Pricing Regulation Against Pharma Challenge, Removing Legal Safety Net
Drug pricing / FDA / IRA · Medium influence · Long term
No direct news naming MRK in this range yet.
Macro, commodity, FX and regulatory forces that moved MRK in this range, with the stories behind each.
Also monitored for MRK (no news in this range): FDA approvals & trial outcomes.
Sign up free to track MRK, unlock full history and the complete driver breakdown, and get alerts when sentiment shifts.
Track MRK for freeInformational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
How news sentiment on Merck & Co. (MRK) has built up over time. Each bar sums the direction of every story TradeTidings published in the period, weighted by how influential we rated it, not just a plain count, so a single high-influence negative story can outweigh several small positive ones. Hover a bar for its exact figures, or click one to filter the stories below to that period. Our own original analysis, not a copied index or a price chart, and not a prediction.
